News for Precigen, Inc. (PGEN)

\n Precigen (PGEN) and the Recurrent Respiratory Papillomatosis Foundation (RRPF) will co-host the 2025 International RRP Awareness Day on June 11 in Washingt

Precigen Inc (PGEN) is set to release its Q4 2024 earnings on Mar 19, 2025. The consensus estimate for Q4 2024 revenue is $0.73 million, and the earnings are ex

U.S. stocks were lower, with the Dow Jones index falling around 400 points on Friday. Shares of Scholastic Corporation SCHL rose sharply during Friday's sessio...

Net Loss: $126.2 million for 2024, compared to $95.9 million in 2023.Net Loss Per Share: $0.47 per basic and diluted share for 2024, compared to $0.39 in 2023.

Mar 19, 2025 / 08:30PM GMTOperator Good evening and welcome to the Precigen's Full Year 2024 Financial Results and Business Update Call. (Operator Instructions)

Precigen, Inc. (NASDAQ:PGEN) Q4 2024 Earnings Conference Call March 19, 2025 4:30 PM ETCompany ParticipantsSteven Harasym - IRHelen Sabzevari - President...

Precigen (PGEN) delivered earnings and revenue surprises of 33.33% and 2.86%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

PR NewswireGERMANTOWN, Md., March 19, 2025 FDA granted priority review to Company's BLA for PRGN-2012 for the treatment of adults with recurrent respirator

Revenue: Total revenues decreased by $2.3 million, or 37%, compared to the previous year, primarily due to reductions in product and service volumes at Exempla

PR NewswireGERMANTOWN, Md., March 13, 2025 GERMANTOWN, Md., March 13, 2025 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company speci

We recently published an article titled Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025. In this article, we are going to take a look at where Precigen, Inc.

Discover groundbreaking advancements in RRP treatment as FDA reviews PRGN-2012.

PR NewswireGERMANTOWN, Md., Feb. 25, 2025 ”“ Priority review reduces the BLA review timeline to 6-months and is granted to therapies that, if approved, wo

Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?

Transaction Overview On December 31, 2024, Patient Capital Management, LLC (Trades, Portfolio) executed a strategic transaction involving Precigen Inc (PGEN). T

Precigen has a market cap of $468mn and a cash runway into 2026, but needs more funds for commercialization. Check out my recommendation for PGEN stock.

U.S. stocks were mixed, with the Dow Jones index gaining around 100 points on Thursday. Shares of Knight-Swift Transportation Holdings Inc. KNX rose sharply du...

Patient Capital Management's Opportunity Equity Strategy surpassed the market to end up 26.5%, 150bps ahead of the S&P 500’s 25.0%. Click here to read the full fund letter.

Precigen to Present Plans for Realizing Commercial Vision for PRGN-2012 at the 43rd Annual J.P. Morgan Healthcare Conference